PicturaBio
- Company typePrivate
- Founded2022
- HeadquartersOxford, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
PicturaBio firmographics
Firmographics- Name
- PicturaBio
- Legal name
- Pictura Bio Ltd
- Website
- https://pictura.bio
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
PicturaBio industry classification
Industry- Product category
- Infectious Disease Diagnostics
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)
- akta.pro secondary industries
- Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
Keywords
Where PicturaBio is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
PicturaBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Diagnostic Device Sales: Sale of VISTA Reader hardware and single-use test cartridges to healthcare facilities including hospitals, GP surgeries, pharmacies, and point-of-care settings.
- Software Updates and Licensing: Revenue from software updates that train the AI to recognize new pathogens. New tests distributed via software update to already deployed systems, enabling continuous platform expansion.
- Government and Defence Contracts: Revenue from contracts with UK Ministry of Defence and DASA for ruggedized diagnostic systems designed for front-line military and field use environments.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
PicturaBio product offering
Product offeringCore offering
Pictura Bio develops and is commercialising a one-minute infectious disease pathogen detection platform combining a proprietary universal fluorescent labelling reagent (PIC-ID Capture), a benchtop fluorescence microscopy instrument (VISTA Reader), and a deep learning image analysis algorithm (PIC-ID Identify). The integrated platform is sold to hospitals, GP surgeries, pharmacies, and defence customers for point-of-care identification of respiratory viruses, bacteria, and other pathogens.
Product overview
PicturaBio offers the world's first one-minute pathogen recognition platform called PIC-ID. The platform comprises three integrated components: PIC-ID Capture (universal fluorescent labeling reagent), VISTA Reader (specialized benchtop fluorescent microscopy instrument), and PIC-ID Identify (deep learning image analysis software). The system works by tagging pathogens with a single universal reagent, capturing their unique fluorescent signatures via microscopy, and using machine learning algorithms to identify and differentiate between multiple pathogens simultaneously. A military variant called IDRIS provides ruggedized field deployment capability. The company is developing VISTA Alpha (near market-ready system expected July 2026) and VISTA Beta (clinical trials-ready system expected July 2026).
Differentiator
Problem solved
Functional benefit
Brands
- PIC-ID: Proprietary universal labelling reagent that binds to pathogens surrounded by biological membranes, creating unique fluorescent signatures for optical analysis. The core patented technology platform.
- VISTA Reader
- PIC-ID Identify
- IDRIS
- IRIS
Products and services
- PIC-ID Platform (Pathogen Identification and Classification) Integrated diagnostic platform combining a proprietary universal fluorescent labelling reagent, a benchtop fluorescence microscopy instrument, and a deep learning image analysis algorithm to deliver one-minute pathogen identification at the point of care. Sold to NHS hospitals, GP surgeries, pharmacies, and defence customers.
- IDRIS (In-Field Diagnostic for Rapid Infection Sensing) Ruggedised, portable diagnostic device for military frontline point-of-care infectious disease detection, built on the patented PIC-ID fluorescent labelling and machine learning platform. Delivers results in under 5 minutes with 99% accuracy from throat and nose swab samples. Sold to UK Ministry of Defence and allied military forces.
- PIC-ID Capture (consumable reagent cartridges) Proprietary single universal fluorescent labelling reagent that binds to pathogens surrounded by biological membranes, creating unique fluorescent signatures for optical analysis. One reagent serves all tests, simplifying inventory versus pathogen-specific primers. Sold as a consumable alongside the VISTA Reader.
Quantifiable outcome
- 97-98% accuracy from 155 patient samples in clinical validation
- +5 more outcomes
Companies that use PicturaBio
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles5 records
PicturaBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
PicturaBio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- NHS PortsmouthcorePartnership with NHS Portsmouth Emergency Department for clinical validation of the Pictura Bio diagnostic platform. Company explicitly mentions this partnership as fundamental to overcoming clinical adoption challenges.
- Queen Alexandra Hospital (Portsmouth)coreClinical trial partner for Novel Technologies for Respiratory Virus Identification (ResVir) study registered as NCT05661032. First large-scale sample collection initiative generating respiratory pathogen dataset for PIC-ID Identify machine learning training.
- John Radcliffe HospitalcoreCollaborated with John Radcliffe Hospital to evaluate the diagnostic method using AI software to identify viruses. Over 200 clinical samples were labelled and analysed, demonstrating >97% accuracy in identifying respiratory viruses.
- University of OxfordcorePictura Bio is a spinout from the University of Oxford. Scientific co-founders Nicolas Shiaelis and Dr. Nicole Robb originated from Oxford. Company maintains connection with Oxford's emerging viruses research group led by Professor Miles Carroll.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
PicturaBio competitors and assessment
Company assessmentDirect peers
- QuantuMDx: QuantuMDx is a UK-based developer of the Q-POC rapid molecular POC platform. As a similarly-sized UK diagnostics challenger targeting decentralized infectious disease and antimicrobial resistance testing, it is closely comparable in stage and go-to-market motion.
- Qiagen: Qiagen's QIAstat-Dx is a syndromic molecular diagnostic platform for respiratory and gastrointestinal infections, directly comparable to PicturaBio's multiplex POC positioning. Both target hospital labs and EDs with rapid, panel-based detection.
- bioMérieux: bioMérieux's BioFire FilmArray is the dominant multiplex syndromic molecular panel for rapid infectious disease diagnostics in hospitals, targeting the same ED/ICU customer segment as PicturaBio's VISTA. Both platforms deliver rapid, sample-to-answer multiplex pathogen identification from a single sample.
- Cepheid (Danaher): Cepheid's GeneXpert is the market-leading rapid molecular point-of-care platform for infectious disease (TB, CT/NG, respiratory viruses, SARS-CoV-2). It competes head-to-head with PicturaBio on turnaround time and decentralization for hospitals and clinics.
- T2 Biosystems: T2 Biosystems uses T2 Magnetic Resonance to detect pathogens (T2Candida, T2Bacteria) directly from whole blood without culture. It is a direct peer in rapid, culture-independent pathogen identification at the hospital bedside.
- Binx Health: Binx Health's io system is a rapid molecular POC platform initially deployed for CT/NG testing at pharmacies, clinics and EDs - directly comparable in targeting decentralized clinical settings with rapid sample-to-answer molecular diagnostics.
Emerging players
- Accelerate Diagnostics: Accelerate Diagnostics' Pheno system provides rapid ID and AST directly from positive blood cultures. It competes in the same rapid-pathogen-identification workflow that PicturaBio's universal-labelling / AI approach ultimately aims to address.
- Specific Diagnostics: Specific Diagnostics develops a rapid phenotypic ID/AST platform using biochemical sensors, targeting bloodstream infection identification and antibiotic susceptibility within hours. It is an emerging peer in the rapid phenotypic pathogen identification space where PicturaBio also competes.
- Oxford Nanopore Technologies: Oxford Nanopore's sequencing-based platform is being adopted for rapid infectious disease surveillance and outbreak response. It is an adjacent, emerging technology converging on rapid decentralized pathogen identification - though via sequencing rather than imaging/AI.
Broad incumbents
- Bruker: Bruker's MALDI Biotyper is a widely deployed rapid microbial identification platform using mass spectrometry in clinical microbiology labs. As a broad incumbent in microbial ID, it competes for the same hospital-lab budget that PicturaBio's VISTA targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
PicturaBio social profiles
Digital presencePicturaBio compliance and trust
Trust signalCompliance1 record
PicturaBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
PicturaBio leadership team
Management profileNumber of profiles
Profiles13 records
PicturaBio subsidiaries and ownership
Company hierarchySubsidiaries1 record
PicturaBio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PicturaBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PicturaBio
What does PicturaBio do?
Pictura Bio develops and is commercialising a one-minute infectious disease pathogen detection platform combining a proprietary universal fluorescent labelling reagent (PIC-ID Capture), a benchtop fluorescence microscopy instrument (VISTA Reader), and a deep learning image analysis algorithm (PIC-ID Identify). The integrated platform is sold to hospitals, GP surgeries, pharmacies, and defence customers for point-of-care identification of respiratory viruses, bacteria, and other pathogens.
Is PicturaBio a public or private company?
PicturaBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was PicturaBio founded?
PicturaBio was founded in 2022. It employs 1 to 10 people.
Where is PicturaBio based?
PicturaBio is headquartered in Oxford, United Kingdom, in the Europe region.
How does PicturaBio make money?
Three revenue lines are on record. Diagnostic Device Sales are the primary driver. The others are software Updates and Licensing and government and Defence Contracts.
Who are PicturaBio's main competitors?
Direct peers on record are QuantuMDx, Qiagen, bioMérieux, Cepheid (Danaher), T2 Biosystems and Binx Health. Emerging players are Accelerate Diagnostics, Specific Diagnostics and Oxford Nanopore Technologies. Bruker is listed as a broad incumbent.
Does PicturaBio have an API?
No public API is recorded for PicturaBio.
What industry is PicturaBio in?
PicturaBio's product category is Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis). Its NAICS code is 334516 and its SIC code is 2835.